@article{adca8a689c89406589231af1e056a881,
title = "Lung cancer committee",
author = "R. Byhardt and R. Komaki and D. Ettinger and D. Johnstone and J. Bradley and A. Franko and L. Gaspar and M. Gillin and C. Langer and E. Layne and B. Movsas and R. Munden and W. Sause and J. Stern and J. Hsu and W. Hartsell and R. Yesner",
note = "Funding Information: In addition to the potential for enhanced tumor control, new adjuvants with unique biologic targets, such as AIs and STMs, may also be less toxic than cytotoxic chemotherapy. Aberrations in key signal transduction pathways provide a growth-advantaged environment for tumor cells. Inhibiting these pathways causes growth arrest, and significant synergy exists with RT. Thus, a future randomized Phase II study could combine either RT, gemcitabine, and carboplatin or RT, gemcitabine, and paclitaxel from L0017 with a promising AI in each arm or with an AI in one arm and an STM in the other arm. As newer and more specific AIs and STMs become available, RTOG will evaluate them. Laboratory projects, funded by an RTOG seed grant and/or National Cancer Institute R01 mechanisms, will identify appropriate molecular targets and agents for future study. If new hypoxic cytotoxics, like tirapazamine, appear promising, they may also be tested. Copyright: Copyright 2018 Elsevier B.V., All rights reserved.",
year = "2001",
doi = "10.1016/S0360-3016(01)01779-5",
language = "English (US)",
volume = "51",
pages = "44--52",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3 SUPPL. 2",
}